Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Prilosec For Chronic Use Needs Explicit Labeling, NDAC, GDAC Advise

This article was originally published in The Tan Sheet

Executive Summary

Chronic use of OTC Prilosec (omeprazole) may benefit patients with gastroesophageal reflux disease provided labeling explicitly lists appropriate warnings, advisory committee members concluded at a switch review for the heartburn drug.
Advertisement

Related Content

Prilosec 1 Switch For Heartburn Prevention, 14-Day Use To Be Considered
Late-Listed Patents Need "Careful Scrutiny" By FDA, Hatch And Waxman Say
AHP Protonix OTC Switch Considered As Long-Term Possibility
Prilosec OTC Launch By July 2002 Predicted By P&G's Lafley
P&G Wins Clairol Bid Without Swapping OTCs
Generic Famotidine Launch Delayed By Pepcid AC Pediatric Exclusivity
Company Consultant Conflict Of Interest Awareness Necessary - Ganley
Prilosec Long-Term Efficacy Acknowledged By FDA Advisory Committees
Prilosec Long-Term Efficacy Acknowledged By FDA Advisory Committees
Prilosec GERD Indication OTC Appropriateness Debated At NDAC Meeting

Topics

Advertisement
UsernamePublicRestriction

Register

PS091828

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel